The FDA release from the pulmonary malignancy study is a clear positive catalyst, removing a long-standing regulatory overhang. The upcoming PDUFA date (May 29, 2026) for the pediatric sBLA adds near-term binary catalyst risk. Traders should watch for the pediatric decision as the next major event.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 28 $3.64entry
- T+1 · 6mo ago +3.57%α +3.33% · $3.77
- T+5 · 6mo ago −7.69%α −7.64% · $3.36
- T+20 · 5mo ago +13.74%α +16.88% · $4.14
- T+60 · 3mo ago +14.01%α +12.28% · $4.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced the FDA released it from a postmarketing requirement for Afrezza, a five-year pulmonary malignancy study in 8,000-10,000 type 2 diabetes patients, eliminating a major regulatory overhang. The only remaining postmarketing requirement is a pediatric efficacy/safety assessment, with a PDUFA target action date of May 29, 2026. Separately, the company provided a clinical update on the INHALE-1st pediatric study, with data expected in late 2027.
Key Facts
- FDA released MannKind from a postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 Afrezza patients
- Only remaining postmarketing requirement is pediatric efficacy/safety assessment (sBLA accepted October 2025, PDUFA date May 29, 2026)
- INHALE-1st study: 8 additional sites activated, up to 100 participants expected, data expected late 2027
Financial Impact
Elimination of a costly, multi-year postmarketing study removes a significant future expense and regulatory risk; no dollar amount disclosed
Risk Factors
- PDUFA decision on pediatric sBLA (May 29, 2026) could result in a Complete Response Letter
- INHALE-1st data not expected until late 2027, limiting near-term pipeline catalysts
- No financial figures disclosed; cost savings from released postmarketing requirement are unquantified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-243074 |
| Document: 0001193125-26-243074-index-headers.html | 0001193125-26-243074 |
| Document: 0001193125-26-243074-index.html | 0001193125-26-243074 |
| Document: 0001193125-26-243074.txt | 0001193125-26-243074 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers